Stimalia develops the first bioelectronic medical device for PTSD, transforming trauma care through minimally invasive neuromodulation that directly addresses the body's dysregulated stress response.
PTSD affects 24 million adults across Europe and the US, costing €350 billion annually. Over 50% remain symptomatic despite current therapies. Our grain-of-rice-sized, battery-free implant provides continuous, adjustable therapy without surgery or side effects.